BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease
The Phase 1 study in healthy volunteers will investigate the safety and tolerability of ABBV-0805. ABBV-0805 is the most advanced within the portfolio of alpha-synuclein targeting antibodies in-licensed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.